Re-test your knowledge
Re-test your knowledge
Summary
Now that you have completed Module 4, Addressing patient concerns, you should have a better understanding of the journey a patient with chronic insomnia may have been through by the time they seek treatment in primary care, the benefits and challenges of the current therapeutic landscape, and how to address questions patients may have about QUVIVIQ™. To test your knowledge, answer the questions below and see how your score has improved.
Ready for the next module?
QUVIVIQ™ in practice: patient cases
QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.3
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to ds.safety.uk@idorsia.com
References
- Koffel E, Bramoweth A D, Ulmer C S. Increasing access to and utilization of cognitive behavioral therapy for insomnia (CBT-I): a narrative review. J Gen Intern Med 2018;33(6):955-962
- National Institute for Health and Care Excellence (NICE). Clinical knowledge summary. Insomnia. Scenario: managing short term insomnia (less than 3 months duration), May 2025. Available at: cks.nice.org.uk. Accessed August 2025
- QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics
© NICE 2023 Daridorexant for treating long-term insomnia. Available from www.nice.org.uk/guidance/ta922. All rights reserved. Subject to Notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/ publication.
UK-DA-00656 | Date of preparation: September 2025
